We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

69 hedge funds and large institutions have $163M invested in Stemline Therapeutics, Inc. in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 23 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

9% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 23

1% less funds holding

Funds holding: 70 → 69 (-1)

52% less capital invested

Capital invested by funds: $338M → $163M (-$175M)

Holders
69
Holders Change
-1
Holders Change %
-1.43%
% of All Funds
2%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
18
Increased
21
Reduced
23
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$9.64M
2
SCA
SAC Capital Advisors
Connecticut
+$6.3M
3
AG
Artal Group
Luxembourg
+$4.54M
4
Jennison Associates
Jennison Associates
New York
+$3.66M
5
Millennium Management
Millennium Management
New York
+$2.29M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$7.09M
2
JP Morgan Chase
JP Morgan Chase
New York
-$6.47M
3
CII
CR Intrinsic Investors
Connecticut
-$3.46M
4
BBA
Baker Bros. Advisors
New York
-$3.35M
5
EI
EAM Investors
California
-$3.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$834K +$141K +5,300 +14%
Invesco
27
Invesco
Georgia
$818K +$187K +7,016 +20%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$805K -$44K -1,649 -4%
Two Sigma Investments
29
Two Sigma Investments
New York
$696K +$948K +35,524 New
Lazard Asset Management
30
Lazard Asset Management
New York
$634K +$863K +32,350 New
BIM
31
BlackRock Investment Management
Delaware
$514K +$8.14K +305 +1%
NI
32
Numeric Investors
Massachusetts
$509K +$692K +25,951 New
BA
33
BlackRock Advisors
Delaware
$458K +$207K +7,771 +50%
SIP
34
Stoneridge Investment Partners
Pennsylvania
$448K +$609K +22,833 New
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$431K -$254K -9,532 -30%
AGM
36
Alpine Global Management
New York
$392K +$534K +20,000 New
EIM
37
Essex Investment Management
Massachusetts
$365K -$30.2K -1,132 -6%
TAM
38
Tocqueville Asset Management
New York
$353K +$160K +6,000 +50%
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$352K -$10.7K -400 -2%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$342K +$29.4K +1,100 +7%
TD Asset Management
41
TD Asset Management
Ontario, Canada
$341K -$40K -1,500 -8%
HVC
42
Healthcare Value Capital
New Jersey
$323K – – –
Morgan Stanley
43
Morgan Stanley
New York
$282K -$458K -17,180 -54%
Charles Schwab
44
Charles Schwab
California
$255K – – –
TA
45
Teachers Advisors
New York
$250K – – –
CD
46
Carl Domino
Florida
$237K +$323K +12,100 New
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
$207K +$282K +10,568 New
Barclays
48
Barclays
United Kingdom
$187K +$254K +9,504 +2,779%
MLICM
49
Metropolitan Life Insurance Company (MetLife)
New York
$156K – – –
NFA
50
Nationwide Fund Advisors
Ohio
$146K +$4.54K +170 +2%
1
2
3 4

STML Hedge Fund Activity: Q4 2013 in Review

69 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2013, worth a combined $163M — down 52% from $338M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of STML and 18 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 21 added.

The largest buyer was Franklin Resources, adding an estimated $9.64M. The largest seller was Citadel Advisors, exiting entirely with an estimated $7.09M sold.

  • 69 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2013, down from 70 in Q3 2013.
  • Funds reported $163M of Stemline Therapeutics, Inc. stock for Q4 2013, down 52% quarter-over-quarter.
  • 18 funds opened new Stemline Therapeutics, Inc. positions in Q4 2013 and 19 closed out, a net change of -1 holder.
  • The largest Stemline Therapeutics, Inc. buyer in Q4 2013 was Franklin Resources, an estimated $9.64M added.
  • The largest Stemline Therapeutics, Inc. seller in Q4 2013 was Citadel Advisors, an estimated $7.09M sold.

Based on aggregated 13F filings for Q4 2013.